LifeMD (NASDAQ:LFMD) Announces Quarterly Earnings Results

LifeMD (NASDAQ:LFMD) issued its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01), FiscalAI reports. The business had revenue of $47.28 million during the quarter, compared to analyst estimates of $49.16 million. LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.

Here are the key takeaways from LifeMD’s conference call:

• Q2 profitability missed expectations: Revenue was $47.3 million, but adjusted EBITDA was a $3.5 million loss due to elevated customer acquisition costs and the $39 introductory weight-management offer.
• LifeMD reduced its full-year 2026 outlook to revenue of $205.5 million–$212.5 million and adjusted EBITDA ranging from a $6 million loss to breakeven, while the XYOSTED launch is expected to require $2 million–$3 million of investment this year.
• Underlying business economics improved, with recurring-bill revenue at approximately 84% of total revenue, gross margin expanding to 89%, and sequential reductions of $1.8 million in advertising and $1.5 million in G&A expenses.
• The $39 weight-management offer shifted new patients toward longer-duration plans, with multi-month selections rising from roughly 25% to 85%; management said recent acquisition costs were about 50% below their June peak.
• Management expects adjusted EBITDA profitability in Q3 and Q4 revenue of $60 million–$64 million with adjusted EBITDA of $3 million–$6 million, supported by women’s health growth, pharmacy expansion, insurance initiatives, and new pharmaceutical partnerships.

LifeMD Stock Performance

Shares of LifeMD stock traded down $0.28 on Thursday, reaching $3.40. 4,971,531 shares of the stock were exchanged, compared to its average volume of 1,098,769. The firm has a market cap of $164.43 million, a PE ratio of 68.01 and a beta of 2.02. The firm’s 50 day moving average is $4.43 and its 200-day moving average is $3.98. LifeMD has a one year low of $2.56 and a one year high of $7.32.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Verition Fund Management LLC increased its stake in shares of LifeMD by 62.0% in the 4th quarter. Verition Fund Management LLC now owns 54,893 shares of the company’s stock valued at $187,000 after purchasing an additional 21,004 shares during the last quarter. Wells Fargo & Company MN grew its position in LifeMD by 71.4% in the fourth quarter. Wells Fargo & Company MN now owns 44,162 shares of the company’s stock valued at $151,000 after acquiring an additional 18,396 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in LifeMD during the second quarter worth about $153,000. Oxford Asset Management LLP bought a new position in shares of LifeMD in the second quarter worth about $168,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of LifeMD by 2,180.0% in the second quarter. New York State Common Retirement Fund now owns 11,400 shares of the company’s stock worth $155,000 after acquiring an additional 10,900 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

More LifeMD News

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: BTIG Research maintained a Buy rating while lowering its price target from $10 to $9. The revised target still implies substantial upside, signaling that the firm views the recent selloff as excessive. Benzinga
• Positive Sentiment: B. Riley also retained a Buy rating and reduced its target from $10 to $8, suggesting continued confidence in LifeMD’s longer-term recovery potential. The Fly
• Positive Sentiment: LifeMD reported approximately 356,000 active subscribers, up 20% year over year, while weight-management subscribers reached about 108,000. Gross margin expanded to roughly 89%, and the company said 95% of new weight-management patients now use branded GLP-1 therapies. LifeMD Second Quarter Results
• Neutral Sentiment: Management expects positive adjusted EBITDA in the second half of 2026 and launched a telehealth collaboration for XYOSTED®. LifeMD ended the quarter with $25.1 million in cash, no debt and $30 million of undrawn revolving credit capacity.
• Negative Sentiment: Second-quarter revenue of $47.3 million declined from $49.0 million a year earlier and missed the approximately $49.2 million consensus estimate. The company posted a $0.16-per-share loss, slightly worse than expectations, while adjusted EBITDA remained negative at about $3.5 million. Zacks Q2 Earnings Report
• Negative Sentiment: LifeMD cut full-year 2026 revenue guidance to $205.5 million-$212.5 million from $220 million-$230 million and reduced adjusted EBITDA guidance to a range of a $6 million loss to breakeven, versus prior guidance of $12 million-$17 million. Third-quarter revenue guidance of $48 million-$51 million is also below consensus.

Wall Street Analyst Weigh In

Several research analysts have recently commented on LFMD shares. B. Riley Financial lowered their target price on shares of LifeMD from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research note on Tuesday, May 26th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of LifeMD in a report on Tuesday. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, LifeMD has an average rating of “Moderate Buy” and a consensus target price of $8.14.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.